Comparative Pharmacology
Head-to-head clinical analysis: HUMALOG MIX 50 50 PEN versus NOVOLOG MIX 50 50.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HUMALOG MIX 50 50 PEN versus NOVOLOG MIX 50 50.
HUMALOG MIX 50/50 PEN vs NOVOLOG MIX 50/50
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Insulin lispro is a rapid-acting insulin analog that lowers blood glucose by binding to insulin receptors on liver, muscle, and adipose tissue, promoting glucose uptake and storage, and inhibiting hepatic glucose production.
Insulin analog with rapid onset of action due to substitution of amino acid proline with aspartic acid at position B28, facilitating faster dissociation from hexamers into monomers after subcutaneous injection. Biphasic formulation containing 50% insulin aspart protamine (intermediate-acting) and 50% insulin aspart (rapid-acting).
Subcutaneous injection, 0.5 to 1 unit/kg/day divided into two doses (before breakfast and before dinner), individualized based on blood glucose levels.
Subcutaneous injection. Typical adult dose: 0.5 to 1 unit/kg/day divided into two injections (with breakfast and dinner). Dose is individualized based on blood glucose levels and patient needs.
None Documented
None Documented
Terminal half-life: 0.5-1.0 hour (insulin lispro); clinical context: short duration due to rapid clearance.
6-8 hours (terminal half-life of protamine-bound fraction; free insulin component half-life ~4-5 minutes).
Renal: 75-80% as metabolites; hepatic: 20-25% via biliary elimination.
Renal: 50-60% as intact insulin, 30-40% as metabolites; biliary/fecal: minimal (<1%).
Category C
Category C
Insulin Analog
Insulin Analog